lipodystrophy syndrome

lipodystrophy syndrome

AIDS A clinical state characterized by redistribution of fat, increased waist size, and loss of fatty tissue from the face, arms and legs, caused by protease inhibitors used to manage HIV-1-infected Pts Clinical Redistribution of fat Adverse effects N&V, maculopapular rash, headache, fatigue, headache, vertigo. See AIDS, Nonnucleoside reverse transcriptase inhibitor.

lipodystrophy syndrome

A side effect encountered in the treatment of HIV patients with protease inhibitors in which they develop abnormal accumulations of body fat (e.g., over the upper back), hypercholesterolemia, hyperglycemia, hypertriglyceridemia, and insulin resistance.

antiretroviral treatment-related lipodystrophy syndrome

HIV-related fat redistribution syndrome.

facial lipodystrophy syndrome

Facial lipoatrophy syndrome.
References in periodicals archive ?
HAART therapy has also been associated with lipodystrophy syndrome of hyperlipidemia and fat redistribution.
A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome.
USPRwire, Wed Feb 03 2016] GlobalData's clinical trial report, "HIV-Associated Lipodystrophy Syndrome Global Clinical Trials Review, H2, 2015" provides an overview of HIV-Associated Lipodystrophy Syndrome clinical trials scenario.
Central obesity is also one aspect of the lipodystrophy syndrome highlighted as significant in the development of met-syn among HIV+ adults (4).
The lipodystrophy syndrome (LSHIV), the redistribution of body fat (increased of centripetal fat--lipohypertrophy and/or reduction of peripheral fat--lipoatrophy) and/or metabolic changes related to lipids profile (dyslipidemia), and glucose intolerance, is one example of these adverse events.
The lipodystrophy syndrome is a well-recognised phenomenon in HIV-1-infected patients receiving antiretroviral therapy (ART).
Classical risk factors are metabolic abnormalities associated with insulin resistance and the lipodystrophy syndrome (visceral obesity, diabetes, dyslipidaemia) [61].
Clinical aspects of the lipodystrophy syndrome Fat accumulation * Abdominal obesity * Dorsocervical pad ('buffalo hump') * Cervical hypertrophy * Lipomas * Breast enlargement Fat loss * Face wasting (reduction or absence of subcutaneous tissue on the cheeks with sparing of the facial musculature) * Loss of subcutaneous fat of extremities * Loss of gluteal mass Biological abnormalities * Glucose intolerance, diabetes, hyperinsulinaemia and increased insulin resistance * Hypertriglyceridaemia * Hypercholesterolaemia: increased LDL cholesterol, decreased HDL cholesterol Table IV.
A report in AIDS by Andrew Carr and colleagues describes the physical and biochemical changes occurring in HIV-positive patients taking PIs, defining lipodystrophy syndrome for the first time.
Facial lipoatrophy, a component of the lipodystrophy syndrome, has now become the "scarlet letter of AIDS," said Dr.
The aim of this study was to evaluate the quality of life in people HIV positive with lipodystrophy syndrome.